Figure 6.

Infusion of CSL112 increases total cholesterol efflux capacity (CEC) regardless of baseline functional apolipoprotein A-I (apoA-I) activity. Participants of phase 1 single ascending dose and multiple ascending dose and phase 2a studies were analyzed as 1 group. Mean total CEC for 2 to 24 h was plotted over dose of CSL112 administered by tertiles of baseline apoA-I–normalized CEC (high-density lipoprotein function)-specific activity at baseline. Shown are individual data points, linear regression lines, and 95% CIs for each tertile calculated using a random effects regression model with tertiles of baseline apoA-I–normalized CEC activity as the random effect and testing the parallelism of slopes hypothesis (difference in slopes; P=0.1242).